Program
netakimab
Its studies are mostly in Psoriasis · Spondylitis, Ankylosing, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| SPH-BIOCAD (HK) | 20 open or running | phase 3since May 28, 2025 | May 28, 2025 | none ahead |
| Biocad | 11 open or running | phase 3since Oct 11, 2024 | Oct 11, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2024First study: phase 3 study in Plaque PsoriasisNew to BiocadBiocad · NCT06640517 · 140 enrolled · Russia
- May 28, 2025SPH-BIOCAD (HK)'s first study: phase 3 study in Plaque PsoriasisNew to SPH-BIOCAD (HK)SPH-BIOCAD (HK) · NCT07008547 · 202 enrolled · China
- Nov 30, 2025Phase 3 study in Spondylitis, AnkylosingSPH-BIOCAD (HK) · NCT07277179 · 113 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07277179Spondylitis, Ankylosing · China | 3 | Completed | SPH-BIOCAD (HK) | Jul 5, 2024 | 113 |
| NCT07008547Plaque Psoriasis · China | 3 | Completed | SPH-BIOCAD (HK) | Mar 28, 2025 | 202 |
| NCT06640517Plaque Psoriasis · Russia | 3 | Active, not recruiting | Biocad | Jun 2026 | 140 |
How it is read
Names in the registry
- “Netakimab”, 3 entries
Conditions, from the studies’ own filings
- Psoriasis, 2 studies
- Spondylitis, Ankylosing, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.